Overview
![](/assets/images/picto-drapeau-france-3a76576a5d60a512053b4612ab58dae5.png)
ABSTRACT
Astatine-211 is a radioisotope emitting high energy alpha particles. In association with an appropriate vector, it can be injected into a patient and transported to a tumor to deliver radiation and destroy it, while sparing the surrounding healthy tissues. To reach this goal, one prerequisite is the control of the chemical steps to conjugate astatine to its biological vector. This is a real challenge owing to the difficulties met in clearly determining the chemical behavior of this element. However, several proofs of concept have demonstrated the high potential of this radionuclide for promising applications in nuclear oncology.
Read this article from a comprehensive knowledge base, updated and supplemented with articles reviewed by scientific committees.
Read the articleAUTHOR
-
François GUÉRARD: CNRS Research Fellow CRCINA, Inserm, CNRS, University of Angers, University of Nantes, Nantes, France - Nuclear Oncology Team
INTRODUCTION
Discovered in 1896 by Henry Becquerel, the phenomenon of radioactivity and its associated ionizing radiation was rapidly exploited for therapeutic purposes with the development of brachytherapy. When a radioactive isotope or radioisotope decays, it generates a particle and/or high-energy electromagnetic radiation that can cause irreparable damage to surrounding tumour cells, leading to their death. Since the early days of nuclear medicine, when the radioactive source was implanted directly into the tumor using a needle, the discipline has evolved towards a more refined use known as vectorized radiotherapy, in which the radioisotope is attached to a vector specific to the type of tumor to be targeted, before being injected into the patient. With this approach, even deep-seated and microscopic tumors can in principle be treated while sparing the surrounding healthy tissue. Depending on the type of tumour to be treated, the choice of radioisotope and vector must be perfectly matched.
Alpha particles emitted during radioactive decay are the most energetic and lethal to cells, but they penetrate biological tissues by only a few tens of micrometers. For this reason, α-particle emitters are effective in the treatment of microtumors encountered in residual disease after conventional treatment, or when the disease evolves into a cancer with micrometastases, as well as in the case of hematological cancers expressed by the production of isolated circulating tumor cells. As irradiation is extremely localized, surrounding healthy cells are spared. A limited number of alpha particle emitters of interest to nuclear medicine have been identified. Among them, astatine-211 has some of the most interesting physical characteristics for this type of application: a half-life of 7.2 h, which is adapted to the biological half-life of a large number of vectors, and two decay branches each leading to the emission of an α particle. In addition, appropriate chemical methods are needed to create the radionuclide-vector pair that will form the radiopharmaceutical to be administered to the patient. However, despite the discovery of astatine in the 1930s, its chemistry remains difficult to understand, the main reason being the absence of stable isotopes, which complicates the study of this element's properties.
A better understanding of this element, which will enable us to optimize the design of vectors radiolabeled with astatine-211, is therefore a major challenge for the development of vectorized radiotherapy for cancer.
In this context, this article discusses :
the phenomenon of radioactivity and the properties of ionizing radiation in cancer treatment;
the chemical element astatine and...
Exclusive to subscribers. 97% yet to be discovered!
You do not have access to this resource.
Click here to request your free trial access!
Already subscribed? Log in!
![](/assets/images/logo-eti-286623ed91fa802ce039246e516e5852.png)
The Ultimate Scientific and Technical Reference
KEYWORDS
vectorized radiotherapy | alpha particles emitter | radiopharmaceuticals
This article is included in
Healthcare technologies
This offer includes:
Knowledge Base
Updated and enriched with articles validated by our scientific committees
Services
A set of exclusive tools to complement the resources
Practical Path
Operational and didactic, to guarantee the acquisition of transversal skills
Doc & Quiz
Interactive articles with quizzes, for constructive reading
Properties and applications of astatine in nuclear medicine
Bibliography
Bibliography
Websites
Nuclear Oncology Research Team http://www.crcina.org
Cyclotron Arronax http://www.cyclotron-nantes.fr
IRSN: knowledge base on radioactivity http://www.irsn.fr
Events
International symposium on radiopharmaceutical sciences. Held every two years. http://www.srsweb.org/meetings/
European symposium on radiopharmacy and radiopharmaceuticals. Held every two years in April. http://www.esrr.info/
Congress of...
Regulations
Institut de Radioprotection et de Sûreté Nucléaire (IRSN): institute covering all risks associated with ionizing radiation used in industry and medicine, as well as natural radiation. http://www.irsn.fr
Patents
Process for isolation and purification of astatine-211. United States Patent Application: 0160053345.
Method of producing radionuclides and apparatus therefore. WO/2018/007643
Method for synthesizing iodo- or astatoarenes using diaryliodonium salts. WO/2017/089492
Directory
Manufacturers – Suppliers – Distributors (non-exhaustive list)
Astate-211. Arronax cyclotron, Saint-Herblain http://www.cyclotron-nantes.fr
Tubular furnace for astatine distillation. Verder France, Carbolite Division [email protected]
Organizations – Federations...
Exclusive to subscribers. 97% yet to be discovered!
You do not have access to this resource.
Click here to request your free trial access!
Already subscribed? Log in!
![](/assets/images/logo-eti-286623ed91fa802ce039246e516e5852.png)
The Ultimate Scientific and Technical Reference